| Company Name: |
TargetMol |
| Tel: |
400-821-0310 15002144251 |
| Email: |
xuexiang.shao@tsbiochem.com |
|
| | [2H6]-Isradipine Basic information |
| Product Name: | [2H6]-Isradipine | | Synonyms: | [2H6]-Isradipine;Isradipine D6Q: What is
Isradipine D6 Q: What is the CAS Number of
Isradipine D6 Q: What is the storage condition of
Isradipine D6;Isradipine-[D6] (Standard) | | CAS: | 1261398-97-3 | | MF: | C19H21N3O5 | | MW: | 371.39 | | EINECS: | | | Product Categories: | | | Mol File: | 1261398-97-3.mol | ![[2H6]-Isradipine Structure](CAS/20211123/GIF/1261398-97-3.gif) |
| | [2H6]-Isradipine Chemical Properties |
| | [2H6]-Isradipine Usage And Synthesis |
| Uses | Isradipine-d6 is the deuterium labeled Isradipine[1]. Isradipine (PN 200-110) is an orally active L-type calcium channel blocker. Isradipine, as a powerful peripheral vasodilator, is a dihydropyridine calcium antagonist with selective actions on the heart as well as the peripheral circulation. Isradipine is a potentially viable neuroprotective agent for Parkinson's disease[2][3][4]. | | References | [1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. DOI:10.1177/1060028018797110
[2] Ilijic E, et al. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol Dis. 2011;43(2):364-371. DOI:10.1016/j.nbd.2011.04.007
[3] Campbell CA, et al. Effects of isradipine, an L-type calcium channel blocker on permanent and transient focal cerebral ischemia in spontaneously hypertensive rats. Exp Neurol. 1997;148(1):45-50. DOI:10.1006/exnr.1997.6611
[4] Hof RP, et al. Selective effects of PN 200-110 (isradipine) on the peripheral circulation and the heart. Am J Cardiol. 1987;59(3):30B-36B. DOI:10.1016/0002-9149(87)90079-8 |
| | [2H6]-Isradipine Preparation Products And Raw materials |
|